Stefan Weber

Newron Licenses Evenamide to Myung In Pharm

Newron Pharmaceuticals, a central nervous system (CNS) focused biopharmaceutical company, and Myung In Pharm, South Korea’s leading CNS pharmaceutical company, today announced that they have entered into a license agreement to develop, manufacture, and commercialize Newron’s schizophrenia treatment evenamide.

Top-Feature

INOSIM GmbH

Predictive Simulation in Pharma Production

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

From Catalogue to Collaboration

Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Myung in Pharm